Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica serovar Typhi elicits full immune response by intranasal vaccination

Clinical and Vaccine Immunology

Volumn 14, Issue 8, 2007, Pages 990-997

  Luo, Fengling ^a   Feng, Yong ^a,b   Liu, Min ^a   Li, Pingfei ^a   Pan, Qin ^a   Jeza, Victor Tunje ^a   Xia, Bing ^b   Wu, Jianguo ^b   Zhang, Xiao Lian ^a  

^a WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G2A; NUCLEOCAPSID PROTEIN; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; BACTERIAL PROTEIN; NUCLEOCAPSID PROTEIN, CORONAVIRUS; PILV PROTEIN, BACTERIA; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BACTERIAL GENE; BACTERIUM PILUS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE FUSION; IMMUNOGENICITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; OPERON; PILV GENE; PRIORITY JOURNAL; PROMOTER REGION; SALMONELLA ENTERICA; SARS CORONAVIRUS; VACCINATION; VACCINE PRODUCTION; VIRUS GENE; VIRUS NUCLEOCAPSID; ANIMAL; BAGG ALBINO MOUSE; BLOOD; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC RECOMBINATION; GENETICS; HUMAN; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; METABOLISM; MUCOSAL IMMUNITY; SALMONELLA TYPHI;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; BACTERIAL PROTEINS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENETIC VECTORS; HUMANS; IMMUNITY, MUCOSAL; MICE; MICE, INBRED BALB C; NUCLEOCAPSID PROTEINS; OPERON; PROMOTER REGIONS (GENETICS); RECOMBINATION, GENETIC; SALMONELLA TYPHI; SARS VIRUS; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VIRAL VACCINES;

EID: 35248873500     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00076-07     Document Type: Article

References (46)

1. Barry, E. M., O. Gomez-Duarte, S. Chatfield, R. Rappuoli, M. Pizza, G. Losonsky, J. Galen, and M. M. Levine. 1996. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908. Infect. Immun. 64:4172-4181.
2. Buchholz, U. J., A. Bukreyev, L. Yang, E. W. Lamirande, B. R. Murphy, K. Subbara, and P. L. Collins. 2004. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. USA 101:9804-9809.
3. Bukreyev, A., E. W. Lamirande, U. J. Buchholz, L. N. Vogel, W. R. Elkins, M. St. Claire, B. R. Murphy, K. Subbarao, and P. L. Collins. 2004. Mucosal immunization of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 26:2122-2127.
4. Dietrich, G., S. Spreng, I. Gentschev, and W. Goebel. 2000. Bacterial systems for the delivery of eukaryotic antigen expression vectors. Antisense Nucleic Acid Drug Dev. 10:391-399.
5. Dietrich, G., I. Gentschev, J. Hess, J. B. Ulmer, S. H. Kaufmann, and W. Goebel. 1999. Delivery of DNA vaccines by attenuated intracellular bacteria. Immunol. Today 20:251-253.
6. Dietrich, G., and W. Goebel. 2000. DNA vaccine delivery by attenuated intracellular bacteria. Subcell. Biochem. 33:541-557.
7. Drabner, B., and C. A. Guzman. 2001. Elicitation of predictable immune responses by using live bacterial vectors. Biomol. Eng. 17:75-82.
8. Eisenstein, T. K. 1999. Mucosal immune defense: the Salmonella typhimurium model, p. 51-109. In Y. Paterson (ed.), Intracellular bacterial vaccine vectors. Wiley-Liss, Inc., New York, NY.
9. Galen, J. E., O. G. Gomez-Duarte, G. A. Losonsky, J. L. Halpern, C. S. Lauderbaugh, S. Kaintuck, M. K. Reymann, and M. M. Levine. 1997. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine 15:700-708.
10. Garmory, H. S., K. A. Brown, and R. W. Titball. 2002. Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol. Rev. 26:339-353.
11. Gonzalez, C., D. Hone, F. R. Noriega, C. O. Tacket, J. R. Davis, G. Losonsky, J. P. Nataro, S. Hoffman, A. Malik, and E. Nardin. 1994. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans. J. Infect. Dis. 69:927-931.
12. Gonzalez, C. R., F. R. Noriega, S. Huerta, A. Santiago, M. Vega, J. Paniagua, V. Ortiz-Navarrete, A. Isibasi, and M. M. Levine. 1998. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana. Vaccine 16:1043-1052.
13. He, Y., J. Li, S. Heck, S. Lustigman, and S. Jiang. 2006. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J. Virol. 80:5757-5767.
14. Hess, J., U. Schaible, B. Raupach, and S. H. Kaufmann. 2000. Exploiting the immune system: toward new vaccines against intracellular bacteria. Adv. Immunol. 75:1-88.
15. Hohmann, E. L., C. A. Oletta, K. P. Killeen, and S. I. Miller. 1996. phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single dose typhoid fever vaccine in volunteers. J. Infect. Dis. 173:1408-1414.
16. Hone, D. M., S. R. Attridge, B. Forrest, R. Morona, D. Daniels, J. T. LaBrooy, R. C. Bartholomeusz, D. J. C. Shearman, and J. Hackett. 1988. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect. Immun. 56:1326-1333.
17. Ishii, K., H. Hasegawa, N. Nagata, T. Mizutani, S. Morikawa, T. Suzuki, F. Taguchi, M. Tashiro, T. Takemori, T. Miyamura, and Y. Tsunetsugu-Yokota. 2006. Induction of protective immunity against severe acute respiratory syndrome coronavirus (SARS-CoV) infection using highly attenuated recombinant vaccinia virus DIs. Virology 351:368-380.
18. Jin, H., C. Xiao, Z. Chen, Y. Kang, Y. Ma, K. Zhu, Q. Xie, Y. Tu, Y. Yu, and B. Wang. 2005. Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. Biochem. Biophys. Res. Commun. 328:979-986.
19. Kaufmann, S. H. E. 1998. Immunity to intracellular bacteria, p. 1335-1371. In W. E. Paul (ed.), Fundamental immunology. Lippincott-Raven, New York, NY.
20. Kim, T. W., J. H. Lee, C.-F. Hung, S. Peng, R. Roden, M.-C. Wang, R. Viscidi, Y.-C. Tsai, L. He, P.-J. Chen, D. A. K. Boyd, and T.-C. Wu. 2004. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J. Virol. 78:4638-4645.
21. Kotton, C. N., and E. L. Hohmann. 2004. Enteric pathogens as vaccine vector for foreign antigen delivery. Infect. Immun. 72:5535-5547.
22. Lee, J. S., K. S. Shin, J. G. Pan, and C. J. Kim. 2000. Surface-displayed viral antigens on Salmonella carrier vaccine. Nat. Biotechnol. 18:645-648.
23. Lee, J.-S., H. Poo, D. P. Han, S.-P. Hong, K. Kim, M. W. Cho, E. Kim, M.-H. Sung, and C.-J. Kim. 2006. Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on Lactobacillus casei induces neutralizing antibodies in mice. J. Virol. 80:4079-4087.
24. Levine, M. M., J. E. Galen, E. Barry, F. Noriega, C. Tacket, M. B. Sztein, S. Chatfield, G. Dougan, G. Losonsky, and K. Kotloff. 1997. Attenuated Salmonella typhi and Shigella as live oral vaccines and as live vectors. Behring Inst. Mitt. 98:120-123.
25. Marra, M. A., S. J. M. Jones, C. R. Astell, R. A. Holt, A. Brooks-Wilson, Y. S. N. Butterfield, et al. 2003. The genome sequence of the SARS-associated coronavirus. Science 300:1399-1404.
26. Morris, C., C. K. Tam, T. S. Wallis, P. W. Jones, and J. Hackett. 2003. Salmonella enterica serovar Dublin strains which are Vi antigen-positive use type IVB pili for bacterial self-association and human intestinal cell entry. Microb. Pathog. 35:279-284.
27. Nardelli-Haefliger, D., J. Benyacoub, R. Lemoine, S. Hopkins-Donaldson, A. Potts, F. Hartman, J. P. Kraehenbuhl, and P. Grandi. 2001. Nasal vaccination with attenuated Salmonella typhimurium strains expressing the hepatitis B virus nucleocapsid: dose response analysis. Vaccine 19:2854-2861.
28. Pan, Q., X.-L. Zhang, H.-Y. Wu, P.-W. He, F. Wang, M.-S. Zhang, J.-M. Hu, B. Xia, and J. Wu. 2005. Aptamers that preferentially bind the type IVB pili and inhibit human monocytic-cell invasion by Salmonella enterica serovar Typhi. Antimicrob. Agents Chemother. 49:4052-4060.
29. Pasetti, M. F., R. J. Anderson, F. R. Noriega, M. M. Levine, and M. B. Sztein. 1999. Attenuated guaBA Salmonella typhi vaccine strain CVD915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses. Clin. Immunol. 92:76-89.
30. Pasetti, M. F., T. E. Pickett, M. M. Levine, and M. B. Sztein. 2000. A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model. Vaccine 18:3208-3213.
31. Peng, H., L. T. Yang, L. Y. Wang, J. Li, J. Huang, Z. Q. Lu, R. A. Koup, R. T. Bailer, and C. Y. Wu. 2006. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology 351:466-475.
32. Pickett, T. E., M. F. Pasetti, J. E. Galen, M. B. Sztein, and M. M. Levine. 2000. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect. Immun. 68:205-213.
33. Saif, L. J. 2004. Animal coronavirus vaccines: lessons for SARS. Dev. Biol. 119:129-140.
34. See, R. H., A. N. Zakhartchouk, M. Petric, D. J. Lawrence, C. P. Mok, R. J. Hogan, et al. 2006. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J. Gen. Virol. 87:641-650.
35. Spruth, M., O. Kistner, H. Savidis-Dacho, E. Hitter, B. Crowe, M. Gerencer, P. Bruhl, L. Grillberger, M. Reiter, C. Tauer, W. Mundt, and P. N. Barrett. 2006. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralizing and protective antibody responses. Vaccine 24:652-659.
36. Surjit, M., B. Liu, P. Kumar, V. T. Chow, and S. K. Lal. 2004. The nucleocapsid protein of the SARS coronavirus is capable of self-association through a C-terminal 209 amino acid interaction domain. Biochem. Biophys. Res. Commun. 317:1030-1036.
37. Sztein, M. B., and G. Mitchell. 1997. Recent advances in immunology: impact on vaccine development, p. 99-125. In M. M. Levine, G. C. Woodrow, J. B. Kaper, and G. S. Cobon (ed.), New generation vaccines. Marcel Dekker, Inc., New York, NY.
38. Tacket, C. O., M. B. Sztein, G. A. Losonsky, S. S. Wasserman, J. P. Nataro, R. Edelman, D. Pickard, G. Dougan, S. N. Chatfield, and M. M. Levine. 1997. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect. Immun. 65:452-456.
39. Takeda, J., Y. Sato, H. Kiyosawa, T. Mori, S. Yokoya, A. Irisawa, M. Miyata, K. Obara, T. Fujita, T. Suzuki, R. Kasukawa, and A. Wanaka. 2000. Antitumor immunity against CT26 colon tumor in mice immunized with plasmid DNA encoding β-galactosidase fused to an envelope protein of endogenous retrovirus. Cell. Immunol. 204:11-18.
40. Tam, C. K. P., J. Hackett, and C. Morris. 2004. Salmonella enterica serovar Paratyphi C carries an inactive shufflon. Infect. Immun. 72:22-28.
41. Wang, J., J. Wen, J. Li, J. Yin, Q. Zhu, H. Wang, et al. 2003. Assessment of immunoreactive synthetic peptide from the structural proteins of severe acute respiratory syndrome coronavirus. Clin. Chem. 49:1989-1996.
42. Yang, L. T., H. Peng, Z. L. Zhu, G. Li, Z. T. Huang, Z. X. Zhao, R. A. Koup, R. T. Bailer, and C. Y. Wu. 2006. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin. Immunol. 120:171-178.
43. Reference deleted.
44. Zhang, X.-L., I. S. M. Tsui, C. M. C. Yip, A.W. Y. Fung, D. K.-H. Wong, X. Dai, Y. Yang, J. Hackett, and C. Morris. 2000. Salmonella enterica serovar Typhi uses type IVB pili to enter human intestinal epithelial cells. Infect. Immun. 68:3067-3073.
45. Zhang, X. L., C. Morris, and J. Hackett. 1997. Molecular cloning, nucleotide sequence, and function of a new site-specific recombinase encoded in the major "pathogenicity island" of Salmonella Typhi. Gene 202:139-146.
46. Zhu, Y., M. Liu, W. Zhao, J. Zhang, X. Zhang, K. Wang, C. Gu, Y. Li, C. Zheng, G. Xiao, H. Yan, J. Zhang, D. Guo, P. Tien, and J. Wu. 2005. Isolation of virus from a SARS patient and genome-wide analysis of genetic mutations related to pathogenesis and epidemiology from 47 SARS-CoV isolates. Virus Genes 30:93-102.